In these three mainstream theories, the lack or aging of HSCs is considered to be the main cause of hematopoietic dysfunction. Looking for a candidate drug that can effectively promote the proliferation of HSCs and enhance the activity of bone marrow hematopoietic function has important practical significance, and it is also an urgent problem to be solved. Although G-CSF, EPO, PLT or direct blood transfusion are the first choice for clinical treatment of bone marrow suppression, these methods are relatively expensive, the effect is not lasting, and need to be applied repeatedly [80, 81], and the side effects they bring are unbearable for most patients.